FDA
-
-
-
-
-
-
-
EMA backs orphan drug status for Vanda's imsidolimab in rare skin disease
-
-
-
-
-
-
-
Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results
-
-
-
-
-
-
-
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines
-
-
-
-
-
-
-
FDA accepts Vanda's drug application for rare skin disorder treatment
-
-
-
-
-
-
-
FDA rejects Vanda's HETLIOZ application for jet lag disorder
-
-
-
-
-
-
-
Vanda submits FDA application for rare skin disorder drug
-
-
-
-
-
-
-
Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting
-
332,363 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

